Protagonist Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Protagonist Therapeutics, Inc.
Public Company Edition: Moderna leveraged its all-time high stock price to raise $1.34bn on the same day it reported data from a Phase I trial of its COVID-19 vaccine. Several other companies also took advantage of biopharma’s rising value.
Acquiring Encycle Therapeutics brings Zealand Pharma a promising IBD asset and expands the breadth of its peptide discovery platform.
Goldfinch’s Kidney Genome Atlas may yield novel therapies for diabetic kidney disease and orphan renal indications, with Gilead holding option rights. Spectrum licenses IP from ImmunGene that could safely harness the potential of interferon therapy in cancer.
Emerging Company Profile: Start-up Landos is raising money through a Series B financing to fund Phase II development of its lead oral, gut-restricted compound and described its plans in a video interview at the Biotech Showcase in San Francisco in January.
- Drug Discovery Tools
- Large Molecule